Cargando…

SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating global pandemic, which has seriously affected human health worldwide. The discovery of therapeutic agents is extremely urgent, and the viral structural proteins are particularly important as potential drug targets....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shilin, Lv, Panpan, Li, Mingxue, Chen, Zihui, Xin, Hong, Reilly, Svetlana, Zhang, Xuemei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832061/
https://www.ncbi.nlm.nih.gov/pubmed/36652729
http://dx.doi.org/10.1016/j.biopha.2023.114242
_version_ 1784867981757513728
author Zhou, Shilin
Lv, Panpan
Li, Mingxue
Chen, Zihui
Xin, Hong
Reilly, Svetlana
Zhang, Xuemei
author_facet Zhou, Shilin
Lv, Panpan
Li, Mingxue
Chen, Zihui
Xin, Hong
Reilly, Svetlana
Zhang, Xuemei
author_sort Zhou, Shilin
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating global pandemic, which has seriously affected human health worldwide. The discovery of therapeutic agents is extremely urgent, and the viral structural proteins are particularly important as potential drug targets. SARS-CoV-2 envelope (E) protein is one of the main structural proteins of the virus, which is involved in multiple processes of the virus life cycle and is directly related to pathogenesis process. In this review, we present the amino acid sequence of the E protein and compare it with other two human coronaviruses. We then explored the role of E protein in the viral life cycle and discussed the pathogenic mechanisms that E protein may be involved in. Next, we summarize the potential drugs against E protein discovered in the current studies. Finally, we described the possible effects of E protein mutation on virus and host. This established a knowledge system of E protein to date, aiming to provide theoretical insights for mitigating the current COVID-19 pandemic and potential future coronavirus outbreaks.
format Online
Article
Text
id pubmed-9832061
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher The Authors. Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-98320612023-01-11 SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development Zhou, Shilin Lv, Panpan Li, Mingxue Chen, Zihui Xin, Hong Reilly, Svetlana Zhang, Xuemei Biomed Pharmacother Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a devastating global pandemic, which has seriously affected human health worldwide. The discovery of therapeutic agents is extremely urgent, and the viral structural proteins are particularly important as potential drug targets. SARS-CoV-2 envelope (E) protein is one of the main structural proteins of the virus, which is involved in multiple processes of the virus life cycle and is directly related to pathogenesis process. In this review, we present the amino acid sequence of the E protein and compare it with other two human coronaviruses. We then explored the role of E protein in the viral life cycle and discussed the pathogenic mechanisms that E protein may be involved in. Next, we summarize the potential drugs against E protein discovered in the current studies. Finally, we described the possible effects of E protein mutation on virus and host. This established a knowledge system of E protein to date, aiming to provide theoretical insights for mitigating the current COVID-19 pandemic and potential future coronavirus outbreaks. The Authors. Published by Elsevier Masson SAS. 2023-03 2023-01-11 /pmc/articles/PMC9832061/ /pubmed/36652729 http://dx.doi.org/10.1016/j.biopha.2023.114242 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Zhou, Shilin
Lv, Panpan
Li, Mingxue
Chen, Zihui
Xin, Hong
Reilly, Svetlana
Zhang, Xuemei
SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
title SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
title_full SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
title_fullStr SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
title_full_unstemmed SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
title_short SARS-CoV-2 E protein: Pathogenesis and potential therapeutic development
title_sort sars-cov-2 e protein: pathogenesis and potential therapeutic development
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832061/
https://www.ncbi.nlm.nih.gov/pubmed/36652729
http://dx.doi.org/10.1016/j.biopha.2023.114242
work_keys_str_mv AT zhoushilin sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment
AT lvpanpan sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment
AT limingxue sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment
AT chenzihui sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment
AT xinhong sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment
AT reillysvetlana sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment
AT zhangxuemei sarscov2eproteinpathogenesisandpotentialtherapeuticdevelopment